{
    "clinical_study": {
        "@rank": "148107", 
        "acronym": "AFFILIATE", 
        "arm_group": [
            {
                "arm_group_label": "Low dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Medium dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High dose", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a blinded study in adult patients with PAH evaluating the relative effects of\n      sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all\n      three times per day [TID]).  In addition, the relative effects on clinical worsening and\n      6-minute walking distance (6MWD) will be assessed."
        }, 
        "brief_title": "Effects of Oral Sildenafil on Mortality in Adults With PAH", 
        "completion_date": {
            "#text": "July 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Arterial Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects  \u2265  18 years of age with any of the following conditions:\n\n          -  Idiopathic Primary Pulmonary Arterial Hypertension (IPAH)\n\n          -  PAH secondary to connective tissue disease\n\n          -  PAH with surgical repair (at least 5 years previously) of atrial septal defect\n             (ASD),ventricular septal defect (VSD), patent ductus arteriosus (PDA) and\n             aorto-pulmonary window\n\n          -  PAH diagnosis confirmed by right heart catheterization  performed within 12 months\n             prior to randomization\n\n          -  Functional Class II-IV;  Baseline 6MWD \u2265 50 m.\n\n        Exclusion Criteria:\n\n          -  Significant (ie, >2+) valvular disease other than tricuspid regurgitation or\n             pulmonary regurgitation\n\n          -  History of cardiac arrest, respiratory arrest, hemodynamic collapse, CPR, ventricular\n             tachycardia, ventricular fibrillation, or permanent atrial fibrillation\n\n          -  History of pulmonary embolism; History of chronic lung disease / restrictive lung\n             disease (eg, chronic obstructive pulmonary disease (COPD) or scleroderma) with\n             impairment of lung function\n\n          -  Treatment with PDE-5 inhibitors for PAH\n\n          -  Treatment with bosentan within 3 months of randomization\n\n          -  Current treatment with nitrates or nitric oxide"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "429", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060487", 
            "org_study_id": "A1481324"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low dose", 
                "description": "sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study", 
                "intervention_name": "sildenafil citrate", 
                "intervention_type": "Drug", 
                "other_name": "Revatio"
            }, 
            {
                "arm_group_label": "Medium dose", 
                "description": "sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study", 
                "intervention_name": "sildenafil citrate", 
                "intervention_type": "Drug", 
                "other_name": "Revatio"
            }, 
            {
                "arm_group_label": "High dose", 
                "description": "sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study", 
                "intervention_name": "sildenafil citrate", 
                "intervention_type": "Drug", 
                "other_name": "Revatio"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Citric Acid", 
                "Sildenafil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pulmonary arterial hypertension", 
            "pulmonary hypertension", 
            "PAH", 
            "sildenafil", 
            "revatio"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481324&StudyName=Effects%20of%20Oral%20Sildenafil%20on%20Mortality%20in%20Adults%20with%20PAH"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multinational, Multicenter Study to Assess the Effects of Oral Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension (PAH)", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2022", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time in weeks from the start of study treatment to date of death due to any cause. Death will be determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).", 
            "measure": "Overall Survival (OS)", 
            "safety_issue": "Yes", 
            "time_frame": "every 3 months up to month 96"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060487"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "TTCW defined as the number of days between first dose of study drug and the occurrence of a predefined clinical worsening event. Predefined clinical worsening events include: death, hospitalization due to worsening PAH or disease progression", 
                "measure": "Time to first clinical worsening (TTCW) event", 
                "safety_issue": "Yes", 
                "time_frame": "every 3 months up to month 96"
            }, 
            {
                "description": "6MWD is the distance a participant can walk in 6 minutes.", 
                "measure": "6 Minute Walk Distance (6MWD) at Months 6 & 12", 
                "safety_issue": "Yes", 
                "time_frame": "Months 6 & 12"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}